Alpha Tau Medical Ltd (DRTS) News

AlphaTau into the FDAs TPLC program: https://www.alphatau.com/single-post/alpha-tau-announces-acceptance-into-fda-s-total-product-life-cycle-advisory-program-to-accelerate-ma

Here is link that explains what that program helps with : https://www.fda.gov/medical-devices/how-study-and-market-your-device/total-product-life-cycle-advisory-program-tap

1st lung cancer patient treated--https://www.alphatau.com/single-post/alpha-tau-treats-first-patient-with-recurrent-lung-cancer

“The treatment makes use of bronchoscopic endobronchial ultrasound to insert the Alpha DaRT sources.

examining its application to an organ such the lung, given its proximity to vital healthy organs, may hopefully open new doors to a global population of patients with otherwise poor treatment options

Emory Univ wants another trial for subpopulation

https://www.alphatau.com/single-post/fda-approval-of-ide-to-initiate-multi-center-investigator-initiated-study-of-alpha-dart-in-immunoco

The big boys are correct. Just a little off ontheir delivery and MOA

https://www.cnbc.com/2024/09/16/radiopharmaceuticals-race-heats-up-as-drugmakers-chase-novartis.html

2nd qtr update

https://www.alphatau.com/single-post/alpha-tau-medical-announces-second-quarter-2024-financial-results-and-provides-corporate-update

Atlanta TV discussing AlphaDart trial at Emory Univ.

https://www.atlantanewsfirst.com/2024/06/25/emory-doctor-hopeful-about-clinical-trial-new-skin-cancer-treatment/

https://clinicaltrials.gov/study/NCT05323253?term=alpha%20tau&intr=alpha%20dart&page=2&rank=20#study-overview

Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers

https://www.alphatau.com/single-post/alpha-tau-announces-publication-in-cancers-journal-of-long-term-safety-and-efficacy-data-in-multiple

DRTS under $3

https://www.alphatau.com/single-post/alpha-tau-medical-announces-first-quarter-2024-financial-results-and-provides-corporate-update

https://www.alphatau.com/single-post/alpha-tau-announces-alpha-dart-treatment-of-first-patient-with-liver-metastases-of-colorectal-cancer

Bassett is one of two Alpha DaRT trial sites in New York State, the other being Memorial Sloan Kettering Cancer Center in New York City.

https://www.allotsego.com/skin-cancer-treatment-trials-open/

March Investor Deck

https://www.alphatau.com/_files/ugd/89ab89_701f2ad74a4c4684b223cb427cf79506.pdf

AlphaTau--Sidoti Conference

https://www.alphatau.com/single-post/alpha-tau-to-participate-in-sidoti-small-cap-conference

OR

https://www.meetmax.com/sched/event_98459/conference_presentations.html?bank_access=0&event_id=98459

This is from 07 DEC (THURS) @ 9:15 AM

Pancreatic Cancer Trial--early results
https://www.alphatau.com/single-post/highly-promising-interim-results-of-alpha-dart-treatment-of-advanced-pancreatic-cancer

Japan’s Pharmaceuticals and Medical Devices Agency (“PMDA”) has accepted Alpha Tau’s submission requesting shonin pre-market approval of Alpha DaRT in patients with recurrent head & neck cancer

https://www.alphatau.com/single-post/atm-submits-to-japanese-pmda-for-pre-market-approval-of-alpha-dart-for-recurrent-head-neck-cancer

CORP UPDATE

https://finance.yahoo.com/news/alpha-tau-medical-announces-third-213000260.html?.tsrc=rss

New video presentation. Updates about Hahn@SAB. New manuf facility.

Alpha Tau adds another manuf facility in U.S. So this is certainly getting ahead (cart before the horse??)
https://www.alphatau.com/single-post/atm-enters-into-long-term-lease-of-site-in-new-hampshire-for-second-u-s-manufacturing-facility

The Hudson site promises to be larger than our existing Lawrence site, and is expected to support our goals of materially scaling up capacity as well as achieving manufacturing redundancy

Hahn joins Science Advisor Board

https://www.marketscreener.com/quote/stock/ALPHA-TAU-MEDICAL-LTD-134583875/news/Alpha-Tau-Medical-Ltd-Announces-Stephen-M-Hahn-Joins-Scientific-Advisory-Board-45136482/

Latest DRTS presentation

2nd patient treated for inoperable pancreatic cancer. 1St was in Montreal

https://www.globenewswire.com/news-release/2023/09/14/2743253/0/en/Alpha-Tau-Treats-First-Patient-with-Advanced-Inoperable-Pancreatic-Cancer-at-Israel-s-Hadassah-Medical-Center.html

Alpha Tau Announces Robust Long-Term Safety and Efficacy Data from Multiple Clinical Trials of Alpha DaRT

New K O L event

CORP UPDATE

https://www.alphatau.com/single-post/alpha-tau-medical-announces-first-quarter-2023-financial-results-and-provides-corporate-update

With our Breakthrough Device Designation for the treatment of certain patients with squamous cell carcinoma, we look forward to swift accrual into our U.S. pivotal ReSTART trial, with the goal of bringing the Alpha DaRT closer to availability for patients as quickly as possible."

The results of the trial demonstrated that the treatment was successfully delivered to ten of ten patients, with a 100% CR observed at 12 and 24 weeks,

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2804784

New buy rating

https://beststocks.com/alpha-tau-medical-receives-buy-rating-and-hig/

Alpha Tau enrolled the 1st patrient in their 30 patient pancreatic cancer trial

https://www.clinicaltrials.gov/ct2/show/NCT04002479.

Read about the milestone here

https://www.alphatau.com/single-post/alpha-tau-jgh-announce-alpha-dart-treatment-of-first-patient-in-pancreatic-cancer-clinical-trial

New video

Treatment of 1st two Patients in its Pivotal Multicenter Recurrent Skin Cancer (ReSTART) Trial

https://www.alphatau.com/single-post/treatment-of-1st-two-patients-in-its-pivotal-multicenter-recurrent-skin-cancer-restart-trial

Cash & equivalents balance of $105.4 million, with runway for at least two years

https://www.alphatau.com/single-post/alpha-tau-medical-announces-full-year-2022-financial-results-and-provides-corporate-update

https://www.alphatau.com/single-post/health-canada-authorization-for-alpha-dart-clinical-trial-for-the-treatment-of-liver-metastases

100% response rate!!!!!!!!!!!!!!!!!!!!!!!!!

Several good pieces of news

https://newsfilter.io/a/265287a70404d81a19c29eab7e95abca

Alpha Tau Medical Ltd. (the “Company”) hereby furnishes the following documents:

(i) notice and proxy statement with respect to the Company’s annual general meeting of shareholders (the “Meeting”) to be held at 4:30 p.m. (Israel time), on November 2, 2022, at the Company’s headquarters at 5 Kiryat Hamada St., Jerusalem 9777605, Israel, describing proposals to be voted upon at the Meeting, the procedure for voting in person or by proxy at the Meeting and various other details related to the Meeting; and
(ii) a proxy card for use in connection with the Meeting.

The proxy statement is furnished with this report of foreign private issuer on Form 6-K (this “Form 6-K”) as Exhibit 99.1 and the proxy cards are furnished with this Form 6-K Exhibits 99.2 and 99.3.

This Form 6-K is incorporated by reference into the Company’s registration statement on Form S-8 (File No. 333-264169).

GOOD READ!!!

https://medium.com/wadepthealth/washington-is-one-of-first-states-to-license-promising-new-cancer-treatment-59c42162e25b

18 JUL--11 AM EASTERN--free to register


https://finance.yahoo.com/news/alpha-tau-hosting-key-opinion-200100611.html

Patient, 60, is given alpha-radiation to target the tumor without harming healthy tissue in ‘historical’ procedure

https://nocamels.com/2022/06/israeli-researchers-use-breakthrough-tech-to-treat-prostate-cancer-for-first-time/

1st Prostate Cancer patient treated!!!!

https://www.prnewswire.com/news-releases/alpha-tau-announces-treatment-of-first-prostate-cancer-patient-with-alpha-dart-301573470.html

On June 16, 2022, Alpha Tau Medical Ltd. (the “Company”) issued a press release titled “Alpha Tau Announces Receipt of Radioactive License to Allow Production in Main Manufacturing Floor at its Jerusalem Site, Amended Radioactive License with Increased Capacity at Lawrence, MA Site.” A copy of this press release is attached to this Form 6-K as Exhibit 99.1.


https://newsfilter.io/a/90df70ad4fbbeb233fae5d6cea6e9dce

https://www.prnewswire.com/news-releases/alpha-tau-announces-fda-approval-of-ide-to-initiate-multi-center-pivotal-study-of-alpha-dart-in-recurrent-cutaneous-scc-301564017.html

NEW MAY 2022 INVESTOR PRESENTATION

Link goes to webpage for PDF download

https://www.alphatau.com/events

DRTS: Alpha Tau: First Alpha DaRT Patients Treated in France as Part of Alpha DaRT Multicenter Skin Cancer Trial

https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20220523090518DRTS&utm_campaign=inplay&utm_medium=social&utm_source=twitter&utm_content=view_page

Form F-1 filed

https://newsfilter.io/a/a2246fdd4e4ed658cd4c86741101f8c0

CantorFitz initiates coverage of AlphaTau

https://biotuesdays.com/2022/04/14/cantor-starts-alpha-tau-medical-at-ow-pt-20/

https://seekingalpha.com/article/4500989-alpha-tau-treating-cancer-with-precision-alpha-radiation?utm_source=stck.pro&utm_medium=referral

https://seekingalpha.com/news/3820441-alpha-tau-medical-gains-as-citi-initiates-coverage-with-a-buy-rating?utm_source=stck.pro&utm_medium=referral

Alpha Tau Medical and Healthcare Capital Corp. Announce Completion of Business Combination

Alpha Tau Is Expected to Commence Trading on Nasdaq Under the Ticker "DRTS" on March 8, 2022

JERUSALEM and WILMINGTON, Del., March 7, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, and Healthcare Capital Corp. (Nasdaq: HCCC) ("HCCC"), a special purpose acquisition company, announced today the successful closing of the previously announced business combination (the “Business Combination”). The combined company will continue to be led by Alpha Tau’s existing management team. Alpha Tau’s ordinary shares and warrants are expected to begin trading on Tuesday, March 8, 2022, on Nasdaq under the ticker symbols "DRTS" and “DRTSW,” respectively.

The transaction, and the various proposals giving effect thereto, were approved by the requisite vote of HCCC stockholders at a special meeting of HCCC’s stockholders held on February 18, 2022. A Current Report on Form 8-K disclosing the full voting results was filed by HCCC with the Securities and Exchange Commission on February 22, 2022. Through completion of the Business Combination, Alpha Tau has raised approximately $90 million in gross cash proceeds.

“We are excited to have reached the successful completion of the merger with HCCC, and appreciate the ongoing support of our existing investors and new joiners to the family, as well as all of the parties involved in bringing this momentous transaction to fruition,” noted Alpha Tau CEO Uzi Sofer. “As we redouble our efforts to bring our Alpha DaRT technology to patients around the world, we are confident that this significant inflow of funds will carry us through a significant number of meaningful milestones.”

Alpha Tau CFO Raphi Levy added, “We are proud to have succeeded in executing on a large fundraising amidst a highly challenging market environment. This will afford us the ability to drive the company forward as we continue to execute on our ambitious plans around the world.”

Advisors--Citigroup acted as lead financial advisor to Alpha Tau. Ladenburg Thalmann also served as financial advisor to Alpha Tau. Value Base M&A Ltd. acted as financial advisor to HCCC on the transaction. Piper Sandler and Cantor Fitzgerald acted as joint placement agents on the PIPE. Cantor Fitzgerald acted as a capital markets advisor to HCCC.

Latham & Watkins LLP and Meitar | Law Offices acted as legal advisors to Alpha Tau. Ellenoff Grossman & Schole LLP and FBC & Co. acted as legal advisors to HCCC. Winston & Strawn LLP acted as legal advisor to the placement agents.

About Alpha Tau Medical Ltd.

Founded in 2016, Alpha Tau is an Israeli medical device company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.

Warrant Duration--
4.2 Duration of Warrants. A Warrant may be exercised only during the period (the “Exercise Period”) commencing on the date that is thirty (30) days after the date hereof, and terminating at 5:00 p.m., New York City time on the earlier to occur of: (x) the date that is five (5) years after the date hereof, (y) the liquidation of the Company, or (z) other than with respect to the Private Placement Warrants to the extent then held by the original purchasers thereof or their Permitted Transferees, the Redemption Date (as defined below) as provided in Section 7.2 hereof (the “Expiration Date”); provided, however, that the exercise of any Warrant shall be subject to the satisfaction of any applicable conditions, as set forth in subsection 4.3.2 below, with respect to an effective registration statement. Except with respect to the right to receive the Redemption Price (as defined below) (other than with respect to a Private Placement Warrant) then held by the original purchasers thereof or their Permitted Transferees in the event of a redemption (as set forth in Section 7 hereof), each outstanding Warrant (other than a Private Placement Warrant) to the extent then held by the Sponsor or its Permitted Transferees in the event of a redemption not exercised on or before the Expiration Date shall become void, and all rights thereunder and all rights in respect thereof under this Agreement shall cease at 5:00 p.m. New York City time on the Expiration Date. The Company in its sole discretion may extend the duration of the Warrants by delaying the Expiration Date; provided, that the Company shall provide at least twenty (20) days prior written notice of any such extension to Registered Holders of the Warrants and, provided further that any such extension shall be identical in duration among all the Warrants.

Warrant Price--
4.1 Warrant Price. Each whole Warrant shall entitle the Registered Holder thereof, subject to the provisions of such Warrant and of this Agreement, to purchase from the Company the number of Ordinary Shares stated therein, at the price of $11.50 per share, subject to the adjustments provided in Section 5 hereof and in the last sentence of this Section 4.1. The term “Warrant Price” as used in this Agreement shall mean the price per share at which Ordinary Shares may be purchased at the time a Warrant is exercised. The Company in its sole discretion may lower the Warrant Price at any time prior to the Expiration Date (as defined below) for a period of not less than twenty (20) days on which banks in New York City are generally open for normal business (a “Business Day”); provided, that the Company shall provide at least twenty (20) days’ prior written notice of such reduction to Registered Holders of the Warrants; and provided further, that any such reduction shall be identical among all of the Warrants.

Warrants--

WHEREAS, HCCC issued 19,530,000 warrants as part of its initial public offering, including (i) 13,750,000 warrants sold by HCCC to the public (the “Public Warrants”) and (ii) 6,800,000 warrants (the “Private Placement Warrants” and, together with the Public Warrants, the “Warrants”) sold by HCCC to Healthcare Capital Sponsor LLC, a Delaware limited liability company (“Sponsor”) in each case, on the terms and conditions set forth in the Existing Warrant Agreement;

Private Warrants--
3.6 Private Placement Warrants. The Private Placement Warrants are identical to the Public Warrants, except that so long as they are held by the Sponsor or any of its Permitted Transferees (as defined below), as applicable, the Private Placement Warrants: (i) may be exercised for cash or on a cashless basis, pursuant to subsection 4.3.1(c) hereof, (ii) may not be transferred, assigned or sold until thirty (30) days after the date hereof, and (iii) shall not be redeemable by the Company; provided, however, that in the case of (ii), the Private Placement Warrants and any Ordinary Shares held by the Sponsor or any of its Permitted Transferees, as applicable, and issued upon exercise of the Private Placement Warrants may be transferred by the holders thereof: